Cargando…
Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the f...
Autores principales: | Santos, E.J.F., Hortegal, E.V., Serra, H.O., Lages, J.S., Salgado-Filho, N., dos Santos, A.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972010/ https://www.ncbi.nlm.nih.gov/pubmed/29742267 http://dx.doi.org/10.1590/1414-431X20187288 |
Ejemplares similares
-
Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019) -
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014) -
Economic Benefits of Switching From Intravenous to Subcutaneous
Epoetin Alfa for the Management of Anemia in Hemodialysis
Patients
por: Prasad, Bhanu, et al.
Publicado: (2020) -
The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020) -
Epoetin Alfa: A Cause of Coronary Artery Thrombosis
por: Siddiqui, Muhammad Umer, et al.
Publicado: (2017)